Positive FDA feedback de-risked the amsulostat program, with a phase IIb trial planned pending funding. Cash runway now extends to FY 2028 after an AUD 8 million raise. Key data readouts for skin scarring, myelodysplastic syndrome, and Parkinson’s disease are expected by year-end.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.